Aki Prihti

Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutics for severe cardiovascular diseases. Aplagon's drug candidate (APAC) uniquely targets the vascular injury sites and cools down thromboinflammatory processes, key underlying drivers in many cardiovascular diseases. Our first target indications are 1) arteriovenous fistula (AVF) maturation, enabling hemodialysis treatment for end-stage kidney disease patients (local administration, specialty indication), and 2) critical limb ischemia (CLI, systemic administration in hospital setting). Promising early AVF-data already exist and EU's flagship funding program EIC Accelerator (grant and equity) is supporting our early CLI-studies. We have three clinical studies ongoing, fourth planned and preparations ongoing for a potentially conditional market approval -targeting clinical study in AVF in 2025.